Lluís Puig1, Matthias Augustin2, Andrew Blauvelt3, Alice B Gottlieb4, Ron Vender5, Neil J Korman6, Diamant Thaçi7, Yang Zhao8, Isabelle Gilloteau9, Bintu Sherif10, Nicole Williams11, Adriana Guana8, Mark G Lebwohl12. 1. Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 2. Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Oregon Medical Research Center, Portland, Oregon. 4. New York Medical College at Metropolitan Hospital, New York, New York. 5. Dermatrials Research Inc., Hamilton, Ontario, Canada. 6. University Hospitals Cleveland Medical Center, Cleveland, Ohio. 7. Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany. 8. formerly with Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 9. Novartis Pharma AG, Basel, Switzerland. 10. RTI Health Solutions, Research Triangle Park, North Carolina. Electronic address: bsherif@rti.org. 11. RTI Health Solutions, Research Triangle Park, North Carolina. 12. Icahn School of Medicine at Mount Sinai, New York, New York.
Abstract
BACKGROUND:Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile. OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis. METHODS:Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis. RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05). LIMITATIONS: Analyses were post hoc. CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.
RCT Entities:
BACKGROUND:Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile. OBJECTIVE: To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis. METHODS:Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis. RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05). LIMITATIONS: Analyses were post hoc. CONCLUSION: This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.
Authors: Eleni Kampylafka; Koray Tascilar; Veronika Lerchen; Christina Linz; Maria Sokolova; Ana Zekovic; Arnd Kleyer; David Simon; Jürgen Rech; Michael Sticherling; Georg Schett; Axel J Hueber Journal: Arthritis Res Ther Date: 2020-09-09 Impact factor: 5.156
Authors: Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris Journal: Dermatol Ther (Heidelb) Date: 2021-01-11
Authors: Bruce Strober; Dhaval Patil; Robert R McLean; Melissa Moore-Clingenpeel; Ning Guo; Eugenia Levi; Mark Lebwohl Journal: Dermatol Ther (Heidelb) Date: 2022-05-13